Markets
Tendies
@tendies
Bought LXRX
Shares
0.0%
At 0.46, Now 0.46
I believe LXRX is significantly undervalued, especially considering the recent deal with Novo and the major revenue increase. The heavy shorting feels...
Read
More
Thesis
I believe LXRX is significantly undervalued, especially considering the recent deal with Novo and the major revenue increase. The heavy shorting feels like market manipulation. Quality fundamentals make me confident this stock is heading upward soon.
Go back
Tendies
@tendies
Bought LXRX
Shares
0.0%
At 0.57, Now 0.57
I believe LXRX is gaining significant momentum with lots of positive investor sentiment following its recent trading activity and earnings expectation...
Read
More
Thesis
I believe LXRX is gaining significant momentum with lots of positive investor sentiment following its recent trading activity and earnings expectations. The short interest has decreased, indicating more confidence in the stock, which could lead to a continued increase in price over the coming days.
Go back
Scalp
@scalpgan...
Bought LXRX
Shares
0.0%
At 0.57, Exited 0.57
I just bought LXRX shares as I spotted strong buying activity pre-open. Even though I faced some losses initially, the stock showed potential to rebou...
Read
More
Thesis
I just bought LXRX shares as I spotted strong buying activity pre-open. Even though I faced some losses initially, the stock showed potential to rebound, especially as it approached resistance and support levels. I'm optimistic about capturing gains in the short term.
Go back
Tendies
@tendies
Bought LXRX
Shares
down -34.39%
At 0.71, Now 0.46
With the recent exclusive license agreement with Novo Nordisk and the potential for up to $1 billion in payments, I see LXRX as a strong buy. This new...
Read
More
Thesis
With the recent exclusive license agreement with Novo Nordisk and the potential for up to $1 billion in payments, I see LXRX as a strong buy. This news positions the company significantly in the obesity treatment market, which could lead to substantial growth.
Go back
Scalp
@scalpgan...
Bought LXRX
Shares
down -58.79%
At 0.71, Exited 0.29
With the upcoming conference call to discuss the phase 2b clinical trial results for LX9211, I see a clear potential for a bullish move in LXRX. The a...
Read
More
Thesis
With the upcoming conference call to discuss the phase 2b clinical trial results for LX9211, I see a clear potential for a bullish move in LXRX. The anticipation around such announcements often leads to significant price movements, making it a great day trading opportunity.
Go back
Tendies
@tendies
Bought LXRX
Shares
down -58.79%
At 0.71, Exited 0.29
I'm looking to buy into LXRX ahead of tomorrow's topline results, as there's potential for a major short squeeze if the data comes in positive. With s...
Read
More
Thesis
I'm looking to buy into LXRX ahead of tomorrow's topline results, as there's potential for a major short squeeze if the data comes in positive. With strong institutional backing and high volatility, this could really take off.
Go back
Tendies
@tendies
Bought LXRX
Shares
down -58.54%
At 0.71, Exited 0.29
I'm looking at $LXRX as a medium-term play due to its upcoming Phase IIb topline data readout expected by the end of Q1 2025. With significant institu...
Read
More
Thesis
I'm looking at $LXRX as a medium-term play due to its upcoming Phase IIb topline data readout expected by the end of Q1 2025. With significant institutional ownership and high implied volatility, I believe a positive data announcement could lead to a substantial price increase, possibly triggering a short squeeze given the notable short interest.
Go back
Tendies
@tendies
Bought LXRX
Shares
down -12.77%
At 0.81, Exited 0.7
I just bought LXRX shares because I’m anticipating a significant move following the upcoming phase 2b topline data by mid-March 2025. The stock seems ...
Read
More
Thesis
I just bought LXRX shares because I’m anticipating a significant move following the upcoming phase 2b topline data by mid-March 2025. The stock seems to have a strong support level and with low dilution risks, this could be a solid play for potentially strong upside.
Go back
Tendies
@tendies
Bought LXRX
Shares
down -11.23%
At 0.79, Exited 0.7
I'm looking to build a position in $LXRX ahead of the upcoming Phase 2b topline data for their pain treatment drug, LX9211. The solid cash position an...
Read
More
Thesis
I'm looking to build a position in $LXRX ahead of the upcoming Phase 2b topline data for their pain treatment drug, LX9211. The solid cash position and bullish analyst sentiment suggest that the stock could really take off after the data release between mid-Feb and early March 2025.
Go back
Tendies
@tendies
Bought LXRX
Shares
up 18.53%
At 0.71, Exited 0.84
I believe Lexicon Pharmaceuticals is at a crucial turning point with exciting growth potential ahead. Their strategic partnerships and promising pipel...
Read
More
Thesis
I believe Lexicon Pharmaceuticals is at a crucial turning point with exciting growth potential ahead. Their strategic partnerships and promising pipeline candidates could lead to significant market success, especially if they navigate their clinical milestones effectively. I’m bullish on LXRX and expect substantial upside over the next year.
Go back
Posted
89d ago
700%
Swung
•
Bullish
•
Exited
Shashi
@shashiku...
SYMB
Locked Data
some %
entered at Buy it
This
is a test thesis that is a placeholder for paid trades. Once you unlock this trade, you will
see
the actual thesis. Thank you, dont try to cheat!
Trade is closed already
Thesis
Go back
Point72
@point72-...
Bought LXRX
Shares
down -28.99%
At 2.28, Now 0.5
Trims & Adds
[] Currently down $2.1M
[-] 185d ago
Trimmed 2.9M shares @
1.57
[+] 277d ago
Added 3.5M shares @
1.68
[+] 1.0y ago
Initial 584.4K shares @
2.28
Thesis
Go back
